807 related articles for article (PubMed ID: 17171704)
1. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
2. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
3. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
4. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
5. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
7. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
[TBL] [Abstract][Full Text] [Related]
9. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
12. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
Stamey TA
Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
[TBL] [Abstract][Full Text] [Related]
13. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic local recurrence of prostate carcinoma after radiation therapy.
Leibovici D; Lee AK; Cheung RM; Spiess PE; Kuban DA; Rosser CJ; Shen Y; Yang Y; Chichakli R; Pisters LL
Cancer; 2005 May; 103(10):2060-6. PubMed ID: 15822114
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
[TBL] [Abstract][Full Text] [Related]
16. Predictors of androgen independence in metastatic prostate cancer.
Sim HG; Lau WK; Cheng CW
BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
[TBL] [Abstract][Full Text] [Related]
18. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
20. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]